Login
S

Sanofi

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$630M
Positions
16
Quarter ended
September 30, 2026
Filed
November 05, 2026

Reported portfolio value by quarter (8 quarters reported)

$630M $166M
Q4 24 Q2 25 Q4 25 Q2 26 Q3 26

$174M in Q4 2024 → $630M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Meiragtx Holdings PLC 21.3% Unchanged 12,197,737 $134M
Inhibrx Biosciences, Inc. 18.4% Unchanged 1,157,926 $116M
Novavax 11.8% Unchanged 6,880,481 $74.4M
Korsana Biosciences 10.1% New 1,994,011 $63.8M
Odyssey Therapeutics Inc. 7.0% Trimmed 0.1% 1,990,200 $44.2M
Anaptysbio 6.6% Unchanged 821,917 $41.3M
Agomab Therapeutics Nv 4.9% Unchanged 2,783,096 $30.9M
First Tracks Biotherapeutics Inc. 4.6% Unchanged 821,917 $29.1M
ET Electra Therapeutics Inc 4.4% New 2,461,948 $27.7M
AT Attovia Therapeutics Inc 2.9% New 1,082,855 $18.6M
LB Latigo Biotherapeutics Inc 1.8% New 672,778 $11.2M
Immuneering Corp 1.8% Unchanged 2,708,559 $11.1M
Maplight Therapeutics Inc. 1.5% Unchanged 912,041 $9.29M
ST Scribe Therapeutics 1.5% New 500,000 $9.2M
Sab Biotherapeutics Inc 1.1% New 2,198,500 $6.97M
Q32 Bio Inc. 0.3% Unchanged 244,083 $2.02M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 05, 2026

Company Action Shares changed Value of change % of portfolio
Korsana Biosciences New +1,994,011 +$63.8M 10.1%
ET Electra Therapeutics Inc New +2,461,948 +$27.7M 4.4%
AT Attovia Therapeutics Inc New +1,082,855 +$18.6M 2.9%
LB Latigo Biotherapeutics Inc New +672,778 +$11.2M 1.8%
ST Scribe Therapeutics New +500,000 +$9.2M 1.5%
Sab Biotherapeutics Inc New +2,198,500 +$6.97M 1.1%
Odyssey Therapeutics Inc. Trimmed −1,718 −$38.2K 7.0%

Q2 2026

quarter ended June 30, 2026 · filed July 28, 2026

Company Action Shares changed Value of change % of portfolio
Odyssey Therapeutics Inc. New +1,991,918 +$37.3M 7.0%
First Tracks Biotherapeutics Inc. New +821,917 +$16.5M 3.1%
E Eledon Exited −814,980 −$2.51M —

Q1 2026

quarter ended March 31, 2026 · filed May 07, 2026

Company Action Shares changed Value of change % of portfolio
Agomab Therapeutics Nv New +2,783,096 +$29.2M 8.7%

Q4 2025

quarter ended December 31, 2025 · filed February 11, 2026

Company Action Shares changed Value of change % of portfolio
Maplight Therapeutics Inc. New +912,041 +$16M 5.2%
Omada Health Inc. Exited −524,903 −$11.6M —
LT Lava Therapeutics N.v. Exited −1,919,455 −$2.99M —

Q3 2025

quarter ended September 30, 2025 · filed November 04, 2025

Company Action Shares changed Value of change % of portfolio
Immuneering Corp New +2,708,559 +$19M 7.3%
I Inozyme, Inc Exited −443,255 −$1.77M —
Igm Biosciences Exited −1,438,975 −$1.61M —

Q2 2025

quarter ended June 30, 2025 · filed July 29, 2025

Company Action Shares changed Value of change % of portfolio
Omada Health Inc. New +524,903 +$9.61M 5.5%

Q1 2025

quarter ended March 31, 2025 · filed May 06, 2025

No position changes this quarter.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support